论文部分内容阅读
本文监测乳腺癌患者血清CA_(15-3)水平,旨在对乳腺癌的诊断和预后,尤其对乳腺癌的疗效观察提供重要的临床应用价值。 资料和方法 一、资料: （一）正常对照组:共30人,均为门诊女性体检者。平均年龄36.93±2.12,询问病史和查体均未见异常。 （二）乳腺癌组:共67人,分为术前、术后、复发转移组。前两组患者均为Ⅰ、Ⅱ期乳腺癌,平均年龄为6.96±2.32,43.59±1.36,43.92±3.11,各组患者均行乳腺癌根治术,且术后病理检查确诊为乳腺癌。 二、方法:取外周静脉血分离血清,-25℃保存待测,采用免疫放射分析法（IRMA）测定。试剂盒由天津DPC公司提供,检测仪器为北京261厂生产的FT-630型微机多探头放免测定仪。
This article monitors serum CA_(15-3) levels in breast cancer patients and aims to provide important clinical value for the diagnosis and prognosis of breast cancer, especially for the observation of the efficacy of breast cancer. Materials and Methods I. Information: (1) Normal control group: A total of 30 people were female medical examiners. The average age was 36.93±2.12. No abnormalities were found in history and physical examination. (B) breast cancer group: A total of 67 people, divided into preoperative, postoperative, recurrence and metastasis group. The first two groups of patients were stage I and stage II breast cancer. The average age was 6.96±2.32, 43.59±1.36, and 43.92±3.11. All patients underwent radical mastectomy, and the pathological examination confirmed breast cancer. 2. Methods: Serum was collected from peripheral venous blood, stored at -25°C, and measured by immunoradiometric assay (IRMA). The kit was provided by Tianjin DPC, and the detection instrument was the FT-630 microcomputer multi-probe radiometric analyzer manufactured by Beijing 261 Factory.